Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
Ymera Pignochino(Candiolo Cancer Institute), Massimo Aglietta(A. O. Ordine Mauriziano di Torino)
Cited by 176